Description
FHD-286 is a BRG1/BRM ATPase inhibitor, which is associated with tumor development and progression.
Product Unit Size | Cost | Quantity | Stock |
---|
FHD-286 is a BRG1/BRM ATPase inhibitor, which is associated with tumor development and progression.
Cas No. | 2671128-05-3 |
---|---|
Purity | ≥98% |
Formula | C24H30N6O6S2 |
Formula Wt. | 562.66 |
IUPAC Name | N-[(2S)-1-[[4-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-2-yl]-1,3-thiazol-2-yl]amino]-3-methoxy-1-oxopropan-2-yl]-1-methylsulfonylpyrrole-3-carboxamide |
Synonym | FHD286 |
Appearance | Off white solid |
Store Temp | -20°C |
---|---|
Ship Temp | Ambient |
Info Sheet |
---|
Rago F, Rodrigues L, Bonney M, et al. Exquisite sensitivity to dual BRG1/BRM ATPase inhibitors reveals broad SWI/SNF dependencies in acute myeloid leukemia. Mol Cancer Res. 2022 Mar 1;20(3):361-372. PMID: 34799403
Matsubara D, Kishaba Y, Ishikawa S, et al. Lung cancer with loss of BRG1/BRM, shows epithelial mesenchymal transition phenotype and distinct histologic and genetic features. Cancer Sci. 2013 Feb;104(2):266-273. PMID: 23163725
Sun A, Tawfik O, Gayed B, et al. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers. Prostate. 2007 Feb 1;67(2):203-213. PMID: 17075831
Selective positive allosteric modulator of AMPA...
Peptide found in molluscs, cardiomodulator.
Peptide, vasopressin analog; V1/2 agonist.
Potent and selective inhibitor
Nav1.7 and Nav1.8 N1+ channel blocker.
AT1 antagonist.
ATM and ATR inhibitor.
Proteasome inhibitor.
Histamine H1 antagonist.
H+/K+ ATPase and ROCK-2 inhibitor.
Tuberculosis antigen
Synthetic glutathione peroxidase mimetic; yeast...
Laminin-derived peptapeptide.
Macrolide; threonyl-tRNA synthetase/ligase inhi...
Chloramphenicol derivative; protein translation...
Vitamin D analog.
Antibacterial (Antimyobacterial) agent.
FLT3, c-Kit, PDGFR inhibitor.
V2 antagonist.
Alkyl sulfonate; DNA alkylator.